BULGARI
23.5.2022 09:40:10 CEST | Business Wire | Press release
In the presence of Her Highness Sheikha Latifa bint Mohammed bin Rashid Al Maktoum, Chairperson of Dubai Culture and Arts Authority (Dubai Culture) and Member of the Dubai Council, Bulgari, the leading Italian brand in the world of jewellery and luxury, and in partnership with Dubai Culture, announced the winner of the first edition of the Bulgari Contemporary Art Award during a ceremony held at the Italy Pavilion at Expo 2020 Dubai. The winner was chosen from a shortlist of three art pieces selected by the award’s jury.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220523005313/en/
The ceremony was attended by His Excellency Giuseppe Finocchiaro, Consul-General, Italian Consulate (Dubai); Paolo Glisenti, Italy’s Commissioner General for Expo 2020 Dubai; Jean Christophe Babin, Group CEO of Bulgari; Lucia Boscaini, Brand Curator at Bulgari; Her Excellency Hala Badri, Director General of Dubai Culture; and Dr Saeed Mubarak bin Kharbash, CEO of the Arts and Literature Sector at Dubai Culture .
A panel of three experts — Giuseppe Moscatello, Nujoom Alghanem and Patricia Millns FRSA — visited the exhibition held from 3 to 8 February at the Van de Goudenberg Art Gallery in the Dubai International Financial Centre to celebrate the participating works. Among the 15 artworks, the committee shortlisted three artists: Juma AlHaj (UAE), Dubai-based Kamal Alzubi (Jordan), and Dubai-based artist Nima Nabavi (Iranian-American), who the jury selected for the winning artwork.
Nima Nabavi received a trophy that celebrates the aesthetic and cultural dialogue between Rome and Dubai by combining a silhouette inspired by Bulgari’s iconic doorways and storefronts with architectural ornaments inspired from Dubai’s Al Fahidi and Al Shindagha Historical Neighbourhoods. The trophy was designed by Emirati designer Kamla AlOlama and produced by Asateer, an Emirati studio founded by Mohammed AlSuwaidi specialising in contemporary products that reflect the rich Emirati heritage.
The trophy uses materials with great cultural significance. A frame is fabricated from the rich woods of the UAE’s national tree, Al Ghaf, an emblem of heritage and perseverance. The design also incorporates native mother-of-pearl inlaid motifs and brass.
Nima Nabavi expressed his happiness at winning the award and thanked Bulgari and Dubai Culture for giving him the opportunity to share his artistic vision. He also extended his gratitude to the experts and jury for selecting his work for the award.
The winning artwork was exhibited at the Italy Pavilion in Expo 2020. The artist was also offered the opportunity to experience Rome through the eyes of Bulgari as part of a week-long journey through the brand’s universe. He will experience the beauty of Bulgari’s colourful gems and visit the DomvsAvrea museum space in the Maison’s flagship store in Rome, as well as attend workshops with Bulgari designers and exclusive tours of historical sites and cultural locations particularly linked with Bulgari’s patronage, initiatives and inspiration. In addition, the winning piece will be exhibited at venues associated with Dubai Culture and Bulgari, according to a pre-defined schedule.
Launched in July 2021, the Bulgari Contemporary Art Award opened the door for UAE national and resident artists to submit artworks under the theme ‘Beauty Connects People’ that had them creatively express how beauty connects people and how cities like Dubai and Rome are linked by their inspirational beauty and innovation.
*Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20220523005313/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom